| New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice |
Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients. |
globenewswire.com |
2025-05-15 13:29:00 |
Czytaj oryginał (ang.) |
| Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology |
Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 8 45.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8 Efficacy and safety results were consistent with Phase 2 results of ZORYVE foam 0.3% in adults and adolescents 12 years of age and older Supplemental New Drug Application (sNDA) for investigational ZORYVE foam 0.3% for psoriasis is under review with U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of May 22, 2025 More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement WESTLAKE VILLAGE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of American Medical Association (JAMA) Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3% as a once-daily monotherapy treatment for psoriasis of the scalp and body. |
globenewswire.com |
2025-05-07 15:18:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript |
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Amanda Sheldon - Head of Corporate Communications Frank Watanabe - President and CEO Todd Edwards - CCO Patrick Burnett - Chief Medical Officer Latha Vairavan - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Tyler Van Buren - TD Cowen Kambiz Yazdi - Jefferies Serge Belanger - Needham Douglas Tsao - H.C. Wainwright Operator Good day and welcome to Arcutis Biotherapeutics' 2025 First Quarter Financial Results Conference Call. |
seekingalpha.com |
2025-05-07 03:00:19 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates |
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-05-06 22:10:47 |
Czytaj oryginał (ang.) |
| Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update |
Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024 Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions All three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expand On April 3, 2025, the patent litigation against Padagis was stayed and the court cancelled all case deadlines, including the trial May 22, 2025 Prescription Drug User Fee Act (PDUFA) action date for ZORYVE foam 0.3% for treatment of individuals with plaque psoriasis of the scalp and body, 12 years and older WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-06 20:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 26,500 restricted stock units of Arcutis' common stock to three newly hired employees. |
globenewswire.com |
2025-05-02 20:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:58 |
Czytaj oryginał (ang.) |
| Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? |
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year. |
zacks.com |
2025-04-24 14:46:07 |
Czytaj oryginał (ang.) |
| Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets |
Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha Vairavan, whose expertise aligns better with Arcutis's current commercial stage and financial goals. Zoryve's performance exceeds expectations, with significant revenue growth and expanded Medicaid coverage, bolstered by a robust sales force. |
seekingalpha.com |
2025-04-19 05:41:16 |
Czytaj oryginał (ang.) |
| Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 |
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. |
globenewswire.com |
2025-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Announces Chief Financial Officer Transition |
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis' chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO until the filing of the Company's first quarter 10-Q and will provide transition support through his departure on May 15, 2025. |
globenewswire.com |
2025-04-10 20:30:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,000 restricted stock units of Arcutis' common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of April 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-04 20:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? |
Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-03 15:05:40 |
Czytaj oryginał (ang.) |
| Arcutis and Padagis Agree to Stay Patent Lawsuit |
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay to the ongoing patent litigation between Padagis and the Company, and the Company has agreed to enter a joint stipulation to stay the case, which was filed in the U.S. District Court for the District of Delaware on April 2, 2025. After the Court enters the joint stipulation, all calendared dates and trial for the patent litigation will be vacated. |
globenewswire.com |
2025-04-02 17:16:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% |
The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-03-28 12:55:22 |
Czytaj oryginał (ang.) |
| Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference |
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025. |
globenewswire.com |
2025-03-27 10:00:00 |
Czytaj oryginał (ang.) |
| Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting |
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contraindications to topical treatments New patient reported outcome data for investigational ZORYVE® (roflumilast) foam 0.3% demonstrated favorable efficacy, safety, and local tolerability data in scalp and body psoriasis In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and children, with more than half experiencing involvement of the scalp WESTLAKE VILLAGE, Calif. and ORLANDO, Fla. |
globenewswire.com |
2025-03-07 10:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average |
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend. |
zacks.com |
2025-03-06 12:30:49 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,000 restricted stock units of Arcutis' common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-05 18:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-03-05 12:56:07 |
Czytaj oryginał (ang.) |
| Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck |
Data from phase 1b study, using ARQ-255 for the treatment of patients with alopecia areata, expected in the 1st half of 2025. The global alopecia areata market size is expected to be worth $6.92 billion by 2034. Full-year 2024 net product revenue of ZORYVE was $166.5 million, which was a year-over-year growth rate of 471%. |
seekingalpha.com |
2025-02-27 08:17:40 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations |
Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sales of $69.4M, a 413% YoY increase, beating sales estimates by $10.8M. ZORYVE has maintained quarterly growth of >40% since Q1 2024. Remarkably only one additional quarter of such robust growth will bring sales to a pace needed to achieve profitability. |
seekingalpha.com |
2025-02-26 16:28:32 |
Czytaj oryginał (ang.) |
| U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis |
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from pivotal Phase 3 trial, pivotal long-term extension study, and Phase 1 pharmacokinetic study If approved, ZORYVE cream 0.05% will be a new topical therapy option for approximately 1.8 million children aged 2 to 5 with atopic dermatitis (AD) in the United States WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA's acceptance of a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the topical treatment of mild to moderate AD in children 2 to 5 years old. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript |
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance & Investor Relations Frank Watanabe - President & Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Serge Belanger - Needham & Co. Uy Ear - Mizuho Kambiz Yazdi - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day and welcome to Arcutis Biotherapeutics 2024 Fourth Quarter and Full Year Financial Results Conference Call. |
seekingalpha.com |
2025-02-26 00:53:05 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates |
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.72 per share a year ago. |
zacks.com |
2025-02-25 20:10:24 |
Czytaj oryginał (ang.) |
| Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. |
globenewswire.com |
2025-02-25 18:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology |
ZORYVE® (roflumilast) cream 0.05% improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints. 39.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpoint. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Arcutis to Present at the TD Cowen 45th Annual Health Care Conference |
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 45th Annual Health Care Conference, taking place March 3-5, 2025. |
globenewswire.com |
2025-02-18 18:35:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet |
The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-17 12:55:27 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? |
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2025-02-13 13:22:15 |
Czytaj oryginał (ang.) |
| Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher |
Arcutis Biotherapeutics (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2025-02-11 12:56:15 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 62,000 restricted stock units of Arcutis' common stock to eight newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-05 18:00:00 |
Czytaj oryginał (ang.) |
| Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin" |
Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is sharing his experience with ZORYVE® (roflumilast) topical foam, 0.3%, to help others learn more about this chronic inflammatory skin condition ZORYVE foam is a once-daily, steroid-free, topical for seborrheic dermatitis uniquely formulated for use anywhere on the body, including hair-bearing areas Seborrheic dermatitis impacts more than 10 million Americans and is the third most common skin condition affecting Blacks WESTLAKE VILLAGE, Calif. , Feb. 4, 2025 /PRNewswire/ -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a partnership with the iconic professional football player, Odell Beckham Jr. ("OBJ"), to help raise awareness of seborrheic dermatitis ("seb derm") a common, chronic, recurrent inflammatory skin disease that can cause flaking, redness, itching, and discoloration of the skin. |
prnewswire.com |
2025-02-04 11:15:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade |
The consensus price target hints at a 37.4% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-01-16 13:01:32 |
Czytaj oryginał (ang.) |
| Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million |
Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. |
globenewswire.com |
2025-01-12 10:30:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 75,500 restricted stock units of Arcutis' common stock to eight newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of January 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-06 18:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Arcutis Stock More Than Doubled in Market Value in One Year |
The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug. |
zacks.com |
2025-01-03 16:40:31 |
Czytaj oryginał (ang.) |
| What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 |
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. |
zacks.com |
2024-12-26 13:32:08 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of December 2, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-06 18:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? |
Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross. |
zacks.com |
2024-11-27 13:01:03 |
Czytaj oryginał (ang.) |
| Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 60.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-27 13:00:57 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors |
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend. |
zacks.com |
2024-11-20 12:31:34 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average |
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, and this suggests a long-term bullish trend. |
zacks.com |
2024-11-20 12:31:33 |
Czytaj oryginał (ang.) |
| Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now |
Arcutis Biotherapeutics (ARQT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2024-11-19 12:56:15 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average |
Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT broke through the 20-day moving average, which suggests a short-term bullish trend. |
zacks.com |
2024-11-19 12:35:43 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? |
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total patient opportunity and the industry trending away from topical steroids, which present lower efficacy and higher risk. |
seekingalpha.com |
2024-11-15 10:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? |
The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-11 13:00:33 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript |
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Serge Belanger - Needham & Co. Kambiz Yazdi - Jefferies Operator Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-07 04:24:04 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates |
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.73 per share a year ago. |
zacks.com |
2024-11-06 20:21:24 |
Czytaj oryginał (ang.) |
| Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update |
Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth of 452% vs. Q3 '23 and 45% vs. |
globenewswire.com |
2024-11-06 18:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 50,000 restricted stock units of Arcutis' common stock as well as options to purchase an aggregate of 50,000 shares of Arcutis' common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-04 18:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release |
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-25 15:06:38 |
Czytaj oryginał (ang.) |
| Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference |
WESTLAKE VILLAGE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report third quarter 2024 financial results and provide a business update on Wednesday, November 6, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. |
globenewswire.com |
2024-10-23 20:00:00 |
Czytaj oryginał (ang.) |
| Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older |
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United States, expanding ZORYVE portfolio availability to over 2 million Canadians living with seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older. |
globenewswire.com |
2024-10-18 12:20:00 |
Czytaj oryginał (ang.) |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 95,000 restricted stock units of Arcutis' common stock as well as options to purchase an aggregate of 38,000 shares of Arcutis' common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-04 20:00:00 |
Czytaj oryginał (ang.) |
| New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types |
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated across all subgroups Data presented at the 2024 European Academy of Dermatology & Venereology Congress WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology and immunology, today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials showing that ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of AD in individuals regardless of race, ethnicity, and Fitzpatrick skin types. |
globenewswire.com |
2024-09-25 05:00:00 |
Czytaj oryginał (ang.) |